To get some idea of the massive potential unleashed by the artificial intelligence revolution, you need look no further than ASX AI stock DXN Ltd (ASX: DXN).

If you’re not familiar with DXN, the company manufactures and operates modular data centres.

And business is booming. Here’s what I mean.

Tipping $5,000 into ASX AI stock DXN in March

Back in March, I hadn’t yet heard of DXN. But I wish I had.

You see, on 24 March, DXN shares closed the day trading for 2 cents apiece.

So, for $5,000, I could have bought 250,000 shares in the ASX AI stock. I would then have watched the share price drop to 1.5 cents by market close on 13 April, cutting my initial $5,000 investment to just $3,500.

But if I’d held tight through those early losses, I would then have watched the stock go on an epic tear.

Indeed, in morning trade today, DXN shares are up another 4.6%, currently changing hands for 45.5 cents apiece.

Which means the 250,000 shares I bought six months ago for just $5,000 would be worth $113,750 today. Or a gain of 2,175%.

Boom!

What’s been sending DXN shares to the moon?

Investors have been bidding up the ASX AI stock as DXN kicks off FY 2027 with growing demand for its modular models across AI infrastructure markets.

“FY26 will be remembered as the year DXN’s long-term investment thesis came into focus,” DXN managing director Shalini Lagrutta said following the release of the company’s full-year results on 31 August.

Lagrutta added:

While revenue for the year was impacted by customer-side project deferrals, our maiden AI HPC contract validated years of investment behind our AI-ready modular platform and drove a five-fold increase in the company’s market capitalisation.

We enter FY27 with our strongest-ever backlog currently sitting at $40.9 million as of 30 August 2026 and a rapidly maturing pipeline of identified projects, of which approximately 21% are AI infrastructure related.

Is the ASX AI stock still a good buy today?

Despite its 20-bagger status, Wilson Asset Management – which is a major shareholder in the ASX AI stock – is still adding to its position.

According to Wilson Asset Management portfolio manager Shaun Weick (quoted by the Australian Financial Review):

We think DXN has the potential to be a multi-bagger from here and is one of the best micro-cap opportunities on the ASX…

They have engineered a modular solution, which critically accelerates the rollout of AI factory capacity. They have been awarded multiple initial contracts which, if delivered successfully in coming months, unlocks gigawatt-scale projects which is a multi-billion-dollar revenue opportunity.

The post If I’d invested $5,000 in this ASX AI stock 6 months ago, I’d have $113,750 today! appeared first on The Motley Fool Australia.

More reading

• Fund managers: 2 exciting ASX shares that could be excellent buys

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It hasn’t been a great start to Thursday’s session for BHP Group Ltd (ASX: BHP) shareholders.

The mining giant’s share price has fallen 2.34% to $60.62 in morning trade, wiping out Wednesday’s 1.39% gain.

The stock is now trading almost 12% below its August high of $68.77, with Thursday’s decline adding to a fairly difficult September.

The selling follows an incident at one of BHP’s major overseas operations, where activities have been suspended.

So, what just happened?

Fatal accident forces mine shutdown

According to Reuters, a worker was killed on Wednesday while carrying out maintenance work at BHP’s Escondida copper mine in Chile.

Escondida is the world’s largest copper mine, located in Chile’s Atacama Desert.

Union officials reported that the accident involved a front-end loader, a large vehicle used to move materials around mine sites.

Following the incident, BHP confirmed that all operational activities at Escondida had been suspended, although it hasn’t said when production might resume.

Under Chilean mining regulations, operations cannot restart following a fatal accident until safety inspectors have confirmed that conditions are safe.

A major blow to BHP’s copper business?

Escondida is one of BHP’s biggest assets, with the mining giant holding a 57.5% stake in the operation.

To put its size into perspective, the mine produced approximately 1.26 million tonnes of copper during FY26.

Copper has also become a huge part of BHP’s business, generating US$18.2 billion in underlying EBITDA, or 54% of the group’s total earnings last financial year.

Looking ahead, BHP is targeting production of between 1 million and 1.1 million tonnes at Escondida in FY27.

However, those forecasts were issued before yesterday’s incident, and the company has yet to indicate whether the shutdown will affect its production targets.

A strike could be next

The shutdown comes at a difficult time, with BHP also facing the possibility of a strike at Escondida.

The mine’s supervisors’ union, which represents around 1,020 workers, has urged members to reject the company’s latest pay offer.

Union members are scheduled to vote between 28 and 30 September, with union leaders urging workers to support strike action.

If the offer is rejected, a mandatory five-day government mediation process would follow before a legal strike could begin.

What happens next for BHP shares?

At $60.62, BHP shares are looking considerably more attractive than they did above $68 last month.

However, I wouldn’t be rushing to buy based on today’s decline alone.

I’d prefer to wait for an update from BHP before deciding whether the recent pullback presents a buying opportunity.

The post BHP shares fall as mining operations grind to a halt appeared first on The Motley Fool Australia.

More reading

• Here are the most popular ASX share superannuation investments in SMSFs
• Bought $5,000 worth of New Hope and BHP shares 5 years ago? Guess how much passive income you’ve already earned!
• Why I’d invest $50,000 of superannuation into these 3 top ASX ETFs
• Soul Patts vs BHP: Which ASX share is best for beginners?
• How much passive income can I earn off an $800,000 superannuation balance?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Mesoblast Ltd (ASX: MSB) share price could be in focus after the company secured US FDA approval for a new potency assay for its commercially approved Ryoncil (remestemcel-L-rknd). This milestone further strengthens quality controls for its flagship cell therapy product.

What did Mesoblast report?

• Received FDA approval for the T-cell Proliferation Inhibition BioAssay (TIBA), a new potency assay for Ryoncil.
• TIBA will be used alongside existing assays to ensure consistent product quality.
• Ryoncil remains the only FDA-approved MSC therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older.
• The new assay supports ongoing manufacturing improvements and quality monitoring for commercial product lots.

What else do investors need to know?

Mesoblast’s updated testing process aims to improve the release and stability monitoring of each batch of Ryoncil. The TIBA assay offers added sensitivity to detect any changes in potency during manufacturing scale-up or when production shifts to new facilities.

Mesoblast continues to develop and expand its cell therapy portfolio, with Ryoncil being evaluated for additional diseases and rexlemestrocel-L in late-stage trials for heart failure and chronic lower back pain.

What’s next for Mesoblast?

The new assay’s FDA approval paves the way for smooth ongoing commercialisation of Ryoncil. Mesoblast remains focused on broadening Ryoncil’s use to other inflammatory conditions and advancing its other cell therapies.

Investors can look for updates as the company works toward new product indications, international partnerships, and continued investment in manufacturing and intellectual property.

Mesoblast share price snapshot

Over the past 12 months, Mesoblast shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO), which is flat over the same period.

View Original Announcement

The post Mesoblast wins FDA nod for new Ryoncil potency test appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 shares tipped by brokers to return 73% and 83%
• Brokers rate these 5 ASX shares as a strong buy, and tip upsides of 28% to 62%
• 7 ASX healthcare stock picks from Bell Potter
• Here are the top 10 ASX 200 shares today
• 3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.